{
    "clinical_study": {
        "@rank": "156307", 
        "acronym": "LV strain", 
        "arm_group": {
            "arm_group_label": "sildenafil therapy", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6  minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months.  Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit.  Each individual will serve as his/her own control."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if patients with pulmonary hypertension and mildly\n      elevated heart pressure known as PCWP will exhibit different patterns on echocardiography\n      and that these patterns will predict treatment response to sildenafil, a drug given for this\n      condition."
        }, 
        "brief_title": "Characterization of Left Ventricular (LV) Strain Patterns in Mildly Elevated Pulmonary Capillary Wedge Pressure (PCWP) and Pulmonary Artery Hypertension (PAH).", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension, Pulmonary Artery", 
            "Ventricular Dysfunction, Left"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Ventricular Dysfunction, Left", 
                "Ventricular Dysfunction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with New York Heart Association/World Health\n             Organization(NYHA/WHO)functional class II-III\n\n          -  Patients with mean pulmonary artery pressure >25 mmHg, pulmonary capillary wedge\n             pressure >15 mmHg \u226418, and pulmonary vascular resistance >3 wood units\n\n          -  Age >18 and <80\n\n          -  Stable on antihypertensives and diuretics>3 months\n\n          -  No evidence of active ischemic heart disease\n\n          -  6 minute walk distance >150 meters and <450 meters\n\n        Exclusion Criteria:\n\n          -  - Left ventricular ejection fraction <50%\n\n          -  Patients with significant restrictive lung disease (FVC<60% predicted) and/or\n             significant obstructive lung disease (FEV1 <55% predicted) within 1 year of\n             enrollment\n\n          -  Poorly interpretable grey scale echocardiographic images\n\n          -  Contraindications to right heart catheterization\n\n          -  Nitroglycerin therapy\n\n          -  Moderate-severe aortic and mitral valve abnormality\n\n          -  Contraindications to submaximal exercise testing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800292", 
            "org_study_id": "13-0006-01", 
            "secondary_id": "986-12"
        }, 
        "intervention": {
            "arm_group_label": "sildenafil therapy", 
            "description": "Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.", 
            "intervention_name": "sildenafil", 
            "intervention_type": "Drug", 
            "other_name": [
                "Revatio", 
                "compound UK-92,480", 
                "Patent 5,250,534", 
                "sildenafil citrate", 
                "NDA 22-473", 
                "C22H30N6O4S.C6H8O7", 
                "C28H38N6O11S"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pulmonary Artery Hypertension", 
            "pulmonary capillary wedge pressure", 
            "sildenafil", 
            "echocardiography", 
            "left ventricular longitudinal wall strain", 
            "strain rate pre and post medical therapy", 
            "speckle tracking"
        ], 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tucson", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85724"
                }, 
                "name": "University of Arizona Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension", 
        "other_outcome": [
            {
                "description": "World Health Organization functional class (I-IV) will be determined at baseline and at 3 months", 
                "measure": "World Health Organization functional class", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Blood will be collected to get BNP (brain natriuretic peptide)lab result at baseline and at 3 months", 
                "measure": "BNP (brain natriuretic peptide)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "overall_official": {
            "affiliation": "University of Arizona", 
            "last_name": "Aiden Abidov, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will have 6 minute walk testing prior to sildenafil therapy and 3 months post-initiation of sildenafil therapy.  Improvement in submaximal exercise capacity on sildenafil therapy is defined as \u2265 30 M increase in 6 minute walk testing.", 
            "measure": "exercise capacity not on/on sildenafil therapy", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Echo parameters will be collected pre-therapy vs 3 months on sildenafil therapy. Changes in ventricular wall motion will be documented with left ventricular (LV) septal and lateral wall longitudinal strain and strain rate, right ventricular strain and strain rate, and LV lateral wall/septal strain and strain rate utilizing speckle tracking techniques values determined by 2D-Echo.", 
            "measure": "Echo parameters:left ventricular septal and lateral wall longitudinal strain and strain rate, RV strain and strain rate, and LV lateral wall/septal strain and strain rate", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "University of Arizona", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Arizona Sarver Heart Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Arizona", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}